Whitney Barton, APRN
Nurse Practitioner · Corbin, KYNPI 1275070229
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 714 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 29.8% of the total. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Boehringer Ingelheim$1K
- Grifols USA, LLC$1K
- Electromed, Inc.$1K
- Mylan Specialty L.p.$886
- plus $3K from 21 others
What the payments were for
- Food & beverage$14,30899%
- Education$1241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 149 | $4,299 |
| GSK | 125 | $2,094 |
| Boehringer Ingelheim | 86 | $1,321 |
| Grifols USA, LLC | 72 | $1,309 |
| Electromed, Inc. | 45 | $1,084 |
| Mylan Specialty L.p. | 47 | $886 |
| Sanofi | 30 | $535 |
| Amgen | 16 | $426 |
| Insmed, Inc. | 23 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $318 |
| Baxter Healthcare | 11 | $249 |
| Verona Pharma, Inc. | 14 | $228 |
| Regeneron Healthcare Solutions, Inc. | 10 | $198 |
| Viatris Specialty LLC | 12 | $191 |
| Merck | 10 | $170 |
| Actelion Pharmaceuticals US, Inc. | 6 | $163 |
| Philips North America LLC | 10 | $162 |
| Inogen, Inc. | 12 | $147 |
| Pulmonx Corporation | 4 | $97 |
| Gilead | 3 | $55 |
| Genentech USA, Inc. | 3 | $48 |
| Paratek Pharmaceuticals, Inc. | 2 | $45 |
| Tempus AI, Inc | 1 | $27 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
| Resmed Corp | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,431 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $264,594 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 22 | $252,094 |
| TezspireTezepelumab-Ekko | 45 | $245,737 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 24 | $218,082 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 256 | $217,592 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 261 | $186,719 |
| Fasenra PenBenralizumab | 18 | $102,228 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 127 | $74,657 |
| Dupixent PenDupilumab | 16 | $59,864 |
| Spiriva RespimatTiotropium Bromide | 90 | $55,166 |
| Ondansetron Hcl | 21 | $29,165 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $20,120 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $13,867 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $12,998 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 450 | $12,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $4,299 | $440,924328 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,321 | $405,728261 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $2,094 | $258,682329 claims |
| Grifols USA, LLCProlastin C | $1,309 | $252,09422 claims |
| MerckDulera | $170 | $5,48213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Corbin
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.